Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib in Waldenström Macroglobulinemia
NCT02439138Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of idelalisib in Waldenström macroglobulinemia (WM), sponsored by Dana-Farber Cancer Institute. Started Oct 2015; status: terminated.
02
Drugs
idelalisib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02439138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02439138.